Cytosorbents Co. (NASDAQ:CTSO - Get Free Report) CFO Peter J. Mariani purchased 20,000 shares of the firm's stock in a transaction that occurred on Friday, December 13th. The stock was acquired at an average price of $0.96 per share, with a total value of $19,200.00. Following the completion of the purchase, the chief financial officer now owns 401,363 shares in the company, valued at $385,308.48. This represents a 5.24 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.
Cytosorbents Stock Performance
Shares of CTSO stock opened at $0.91 on Tuesday. The company has a debt-to-equity ratio of 1.06, a quick ratio of 1.58 and a current ratio of 1.97. The company has a market capitalization of $49.74 million, a price-to-earnings ratio of -2.53 and a beta of 0.57. Cytosorbents Co. has a one year low of $0.70 and a one year high of $2.15. The company's 50-day moving average is $0.97 and its 200 day moving average is $1.02.
Institutional Investors Weigh In On Cytosorbents
A number of institutional investors have recently made changes to their positions in the company. Sargent Investment Group LLC lifted its position in Cytosorbents by 13.4% in the 3rd quarter. Sargent Investment Group LLC now owns 1,626,247 shares of the medical research company's stock valued at $2,439,000 after acquiring an additional 192,747 shares in the last quarter. Atomi Financial Group Inc. purchased a new position in shares of Cytosorbents in the third quarter worth $51,000. Geode Capital Management LLC lifted its holdings in shares of Cytosorbents by 7.5% during the third quarter. Geode Capital Management LLC now owns 467,058 shares of the medical research company's stock valued at $701,000 after purchasing an additional 32,415 shares in the last quarter. Finally, CM Management LLC boosted its position in shares of Cytosorbents by 3.0% during the second quarter. CM Management LLC now owns 850,000 shares of the medical research company's stock valued at $598,000 after buying an additional 25,000 shares during the last quarter. Hedge funds and other institutional investors own 32.87% of the company's stock.
Analysts Set New Price Targets
I was wrong. Dead wrong.
From Porter & Company | Ad
I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was.
Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again.
Here’s the full story for you.
CTSO has been the subject of a number of analyst reports. StockNews.com initiated coverage on shares of Cytosorbents in a research note on Thursday, December 12th. They set a "hold" rating for the company. HC Wainwright reiterated a "neutral" rating and set a $1.00 price objective on shares of Cytosorbents in a research note on Monday, November 11th.
Read Our Latest Stock Report on Cytosorbents
About Cytosorbents
(
Get Free Report)
Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
